PREVACID NAPRA PAC
Manufacturer Details
TAP PHARMA INC
Compositions:
Naproxen 375mg/500mg - Lanzoprazole 15mg delayed release capsules in blister pack,
|
Strength
|
Rate
|
Packing Style
|
|
375mg/500mg
|
0.00
|
Delayed release capsules in blister pack
|
List of Related Indications:
- Non-steroidal anti-inflammatory drug -associated gastric ulcers
List Of Drugs:
- Naproxen / Lanzoprazole - NSAIDs Combinations
Indication Type Description:
Drug Interaction:
Cytochrome P450 -
Excercise caution when coadministering celecoxib and mefenamic acid with drugs known
to inhibit the isoenztme 2C9
Drug interactions - summary-
NSAIDs +
Methotrexate
risk of methotrexate toxicity eg stomatitis, bone marrow suppresion, nephrotoxicity may
be increased . Celecoxib and meloxicam did not have a significant effect on methotrexate
pharmacokinetics
NSAIDs - indomethicin + Penicillamine
indomethicin may increase bioavailibility of penicillinamine
NSAIDS - indomethicin./ diclofenac
effects of potassium spaing -diuretics decreased. Co-admin may increase serum potassium levels.
Thiazide diuretics
decreased anti-hypertensive and diuretic action of thiazides may occur with concurrent
indomethicin. Naproxen also included. Sulindac may enhance effects of thiazide
Indication:
Non-steroidal anti-inflammatory drug -associated gastric ulcers
Adverse Reaction:
Refer - Naproxen and Lansoprazole
Contra-Indications:
Refer - Naproxen and Lansoprazole
Dosages/ Overdosage Etc:
Indication-
Non-steroidal anti-inflammatory drug -associated gastric ulcers
Dosage-
Usual dosage- each daily dose consists of one lansoprazole 15mg capsule and two of either
naproxen 375mg or 500mg tablets
Pregnancy and lactation:
Refer - Naproxen and Lansoprazole
